Moleculin Biotech
Seite 4 von 33 Neuester Beitrag: 25.04.21 03:16 | ||||
Eröffnet am: | 17.11.16 18:08 | von: Balu4u | Anzahl Beiträge: | 802 |
Neuester Beitrag: | 25.04.21 03:16 | von: Sabrinamfvb. | Leser gesamt: | 224.694 |
Forum: | Hot-Stocks | Leser heute: | 184 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 | 7 | 8 | 9 | ... 33 > |
Bin auch raus. Hab 350 Euro minus. Is zwar im Vergleich zu meinen gewinnen eher nichtig, aber ich habe mir mehr erwartet und deshalb nehm ich hier lieber meinen Hut...
Ganz ehrlich.......
da drück ich lieber heut abend dem hiesigen obdachlosen vorm Galeria Kaufhof mal wieder nen fuchziger in die Hand als dass ich hier zuseh wie er verbrannt wird......
Ganz ehrlich.......
da drück ich lieber heut abend dem hiesigen obdachlosen vorm Galeria Kaufhof mal wieder nen fuchziger in die Hand als dass ich hier zuseh wie er verbrannt wird......
Der mehrfache Verkauf des Aktienbestandes ist möglicherweise der Beginn einer hysterische Rückkaufaktion!!! Denn, der Verkauf von Aktien, die nicht im Besitz waren, sollte zu irgendeinem Zeitpunkt deren Rükauf erzwingen!!! Die Frage sei nur wann!!!! Es sei denn, das Unternehmen sein ein Flop!!!! Meine persönliche Meinung, aber keine Empfehlung zu irgendeiner Handlung!!!!
Das Unternehmen is keineswegs ein Flop. Der Kurs flopt halt nur momentan und da muss ich nicht wirklich dabei sein.
Lieber raus, nächstes mal mit meinem üblichen Einsatz +Verlust wieder rein, und es bügelt sich von alleine wieder aus.
Ich geb heut lieber dem einen nen fuffi in die Hand als dass 7ch zusehen wie er hier flöten geht :))
Lieber raus, nächstes mal mit meinem üblichen Einsatz +Verlust wieder rein, und es bügelt sich von alleine wieder aus.
Ich geb heut lieber dem einen nen fuffi in die Hand als dass 7ch zusehen wie er hier flöten geht :))
Unterstützung und in der verbleibenden Stunde sehe ich eher Käufe als Verkäufe in Voraussicht auf den Montag.
Tippe mal auf ein Schluß zwischen 1,45 und 1,50 ..und dann Erholung am Montag.
Das Kaufinteresse in der letzten Stunde war schon hoch.
Lege auch nochmal 10k nach, das ist zu verlockend und zwingende short-Adressen kann ich nicht ausmachen, diedas letzte setzen. Dafür ist die Aktie bzw. Unternehmen zu gut.
Tippe mal auf ein Schluß zwischen 1,45 und 1,50 ..und dann Erholung am Montag.
Das Kaufinteresse in der letzten Stunde war schon hoch.
Lege auch nochmal 10k nach, das ist zu verlockend und zwingende short-Adressen kann ich nicht ausmachen, diedas letzte setzen. Dafür ist die Aktie bzw. Unternehmen zu gut.
Handelstag Eröffnung Schluss gehandeltes Aktienzahl
07.07.17 1,64 1,45 $ 1.642.828
06.07.17 1,65 1,64 $ 2.486.157
05.07.17 2,00 1,62 $ 2.628.545
03.07.17 1,95 1,90 $ 2.674.836
30.06.17 2,18 1,87 $ 8.095.871
29.06.17 2,97 2,97 $ 20.159.016
28.06.17 1,86 3,28 $ 34.866.206
27.06.17 1,64 1,98 $ 25.268.706
26.06.17 1,25 1,52 $ 5.539.895
23.06.17 1,01 1,10 $ 1.727.557
22.06.17 1,05 1,01 $ 3.012.294
21.06.17 1,14 1,04 $ 17.275.544
Fragen über Fragen:
Dennoch die entsacheidende Frage ist doch: Wie oft wurde der Aktienbestand innerhalb weniger Tage verkauft???
Eure Leserart dessen und deren möglichen Fortsetzungen/Szenarien!!!
07.07.17 1,64 1,45 $ 1.642.828
06.07.17 1,65 1,64 $ 2.486.157
05.07.17 2,00 1,62 $ 2.628.545
03.07.17 1,95 1,90 $ 2.674.836
30.06.17 2,18 1,87 $ 8.095.871
29.06.17 2,97 2,97 $ 20.159.016
28.06.17 1,86 3,28 $ 34.866.206
27.06.17 1,64 1,98 $ 25.268.706
26.06.17 1,25 1,52 $ 5.539.895
23.06.17 1,01 1,10 $ 1.727.557
22.06.17 1,05 1,01 $ 3.012.294
21.06.17 1,14 1,04 $ 17.275.544
Fragen über Fragen:
Dennoch die entsacheidende Frage ist doch: Wie oft wurde der Aktienbestand innerhalb weniger Tage verkauft???
Eure Leserart dessen und deren möglichen Fortsetzungen/Szenarien!!!
NEW YORK, NY / ACCESSWIRE / July 12, 2017 / Therapeutics MD soared on Tuesday after an analyst gave an upbeat rating on the stock as well as a price tag more than 100% higher than current share prices. Moleculin Biotech also saw big gains despite any big news but the company has been releasing significant press releases in the last few weeks, including one that reveals the company has discovered a metabolic inhibitor with the potential to treat pancreatic cancer.
RDI Initiates Coverage on:
TherapeuticsMD, Inc.https://ub.rdinvesting.com/news/?ticker=TXMD
Moleculin Biotech, Inc.https://ub.rdinvesting.com/news/?ticker=MBRX
TherapeuticsMD, Inc.'s shares closed in the green up 3.96% yesterday. Shares were up as much as 18.75% when the stock hit $5.70 during intra-day trading. The big move came after traders found out that an analyst at Oppenheimer upgraded the stock from "perform" to "outperform." He also gave shares a $10 price target which would be a major increase from current share prices. Jay Olson of Oppenheimer believes that there could be positive news from TherapeuticsMD's meeting with the FDA on or around the 14th of this month. According to Oppenheimer, the company will likely resubmit TX-004HR by the 31st and there could be a possible FDA approval by September 29. Olson says the probability of this is 60%. TX-004HR was rejected by the FDA a few months back as there were concerns that there was a lack of long-term endometrial safety data. TX-004HR is an investigational applicator-free estradiol vaginal soft gel capsule that is intended to treat moderate-to-severe vaginal pain.
Access RDI'sTherapeuticsMD, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=TXMD
Moleculin Biotech, Inc.'s shares closed up 8.45% on Tuesday despite any remarkable news. It was earlier this month however that the preclinical pharma company announced that it has appointed Dr. Lidia Gil from Poznan University of Medical Sciences in Poland to be the leader of its European Principal Investigator (PI) for the planned Phase I/II clinical trial of Annamycin. Annamycin is an anthracycline that is being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. CEO Walter Klemp commented, "Dr. Gil is a highly-respected hematologist-oncologist in Poland and we are honored to have her leading the European element of our upcoming clinical trial for Annamycin, which would commence only if our IND is permitted."
Dr. Gil Commented, "We are so pleased to be hosting the planned Annamycin clinical trial here in Poland. The absence of an approved second-line therapy for relapsed or refractory AML patients represents a significant unmet need and demonstrating activity in this trial could represent a major development in the treatment of AML."
It was also last month that the company announced that it has discovered a metabolic inhibitor with the potential to treat pancreatic cancer.
Access RDI'sMoleculin Biotech, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=MBRX
Our Actionable Research on TherapeuticsMD, Inc. (NYSE:TXMD) and Moleculin Biotech, Inc. (NASDAQ:MBRX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@rdinvesting.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE:RDInvesting.com
This article appears in: News Headlines
Referenced Stocks: MBRX, TXMD
RDI Initiates Coverage on:
TherapeuticsMD, Inc.https://ub.rdinvesting.com/news/?ticker=TXMD
Moleculin Biotech, Inc.https://ub.rdinvesting.com/news/?ticker=MBRX
TherapeuticsMD, Inc.'s shares closed in the green up 3.96% yesterday. Shares were up as much as 18.75% when the stock hit $5.70 during intra-day trading. The big move came after traders found out that an analyst at Oppenheimer upgraded the stock from "perform" to "outperform." He also gave shares a $10 price target which would be a major increase from current share prices. Jay Olson of Oppenheimer believes that there could be positive news from TherapeuticsMD's meeting with the FDA on or around the 14th of this month. According to Oppenheimer, the company will likely resubmit TX-004HR by the 31st and there could be a possible FDA approval by September 29. Olson says the probability of this is 60%. TX-004HR was rejected by the FDA a few months back as there were concerns that there was a lack of long-term endometrial safety data. TX-004HR is an investigational applicator-free estradiol vaginal soft gel capsule that is intended to treat moderate-to-severe vaginal pain.
Access RDI'sTherapeuticsMD, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=TXMD
Moleculin Biotech, Inc.'s shares closed up 8.45% on Tuesday despite any remarkable news. It was earlier this month however that the preclinical pharma company announced that it has appointed Dr. Lidia Gil from Poznan University of Medical Sciences in Poland to be the leader of its European Principal Investigator (PI) for the planned Phase I/II clinical trial of Annamycin. Annamycin is an anthracycline that is being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. CEO Walter Klemp commented, "Dr. Gil is a highly-respected hematologist-oncologist in Poland and we are honored to have her leading the European element of our upcoming clinical trial for Annamycin, which would commence only if our IND is permitted."
Dr. Gil Commented, "We are so pleased to be hosting the planned Annamycin clinical trial here in Poland. The absence of an approved second-line therapy for relapsed or refractory AML patients represents a significant unmet need and demonstrating activity in this trial could represent a major development in the treatment of AML."
It was also last month that the company announced that it has discovered a metabolic inhibitor with the potential to treat pancreatic cancer.
Access RDI'sMoleculin Biotech, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=MBRX
Our Actionable Research on TherapeuticsMD, Inc. (NYSE:TXMD) and Moleculin Biotech, Inc. (NASDAQ:MBRX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@rdinvesting.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE:RDInvesting.com
This article appears in: News Headlines
Referenced Stocks: MBRX, TXMD
Normalerweise müsste sie längst durch fie Decke gehen. Aber jemand shortet das Teil bis der Arzt kommt. Maschinen-Handel ... pausenlose 100..100...100...100... ins Bit... die ganzen Tage schon....
ist einfach ne irre Börsenzeit. Entweder du sitzt auf einem Trend wie Xing oder Apple oder Adidas , wo es von einem Hoch zum Nächsten geht,
bei den Anderen Aktien ist man meißt auf der kurzen Seite besser auf gehoben. So Funktioniert der moderne Handel wohl.
bei den Anderen Aktien ist man meißt auf der kurzen Seite besser auf gehoben. So Funktioniert der moderne Handel wohl.
Kurzen short automatisch mit nach Unten gelaufen zum Verlustausgleich und zwischen 1,51 und 1,53 nochmals um 20k aufgestockt. Passt. Die kommt schon noch und für die habe ich schon noch ein größeres Budget vorgesehen.